Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Tango Therapeutics, Inc. | Director | Common Stock | 6.99M | $58.6M | $8.39 | Jun 6, 2023 | Indirect |
Odonate Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 4.61M | $7.23M | $1.57 | Nov 19, 2021 | Indirect |
Odonate Therapeutics, Inc. | Director, 10%+ Owner | Common Stock | 446K | $699K | $1.57 | Nov 19, 2021 | Direct |
Tango Therapeutics, Inc. | Director | Common Stock | 5K | $42K | $8.39 | Jun 6, 2023 | Direct |
Rain Oncology Inc. | Director | Common Stock, par value $0.001 per share | 0 | $0 | $1.21 | Jan 26, 2024 | Direct |
Tango Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 30K | Jun 6, 2023 | Direct | ||
iTeos Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 24.2K | Jun 11, 2024 | Direct | ||
Mirati Therapeutics, Inc. | Director | Common Stock | 0 | $59.02 | Jan 23, 2024 | Direct | |
Mirati Therapeutics, Inc. | Director | Option to Purchase Common Stock | 0 | Jan 23, 2024 | Direct | ||
Rain Oncology Inc. | Director | Stock Option (Right to Buy) | 0 | Jan 26, 2024 | Direct |